ASLAN Falls As TreeTopp BTC Study Fails
TreeTopp Varlitinib Trial In Biliary Tract Cancer Missed Endpoints
ASLAN’s pivotal Phase II TreeTopp study of varlitinib in biliary tract cancer missed its co-primary endpoints of progression-free survival and overall response rate.
You may also be interested in...
Following a major setback in another indication earlier this year, ASLAN’s lead asset is now seen as a potential new option for second-line use in biliary tract cancer following promising new data from a Chinese trial.
Novo Nordisk’s CEO talks to Scrip about the promise of glucose-responsive insulin, stem cell therapy, and a diabetes landscape without Sanofi.
The US FDA has slapped a partial clinical hold on Ipsen’s palovarotene clinical trials in rare bone disorders in children less than 14 years old, due to bone growth concerns.